246 related articles for article (PubMed ID: 11735417)
1. Characterization of hK4 (prostase), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase.
Takayama TK; McMullen BA; Nelson PS; Matsumura M; Fujikawa K
Biochemistry; 2001 Dec; 40(50):15341-8. PubMed ID: 11735417
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein.
Takayama TK; Fujikawa K; Davie EW
J Biol Chem; 1997 Aug; 272(34):21582-8. PubMed ID: 9261179
[TBL] [Abstract][Full Text] [Related]
3. Activation of prostate-specific antigen precursor (pro-PSA) by prostin, a novel human prostatic serine protease identified by degenerate PCR.
Takayama TK; Carter CA; Deng T
Biochemistry; 2001 Feb; 40(6):1679-87. PubMed ID: 11327827
[TBL] [Abstract][Full Text] [Related]
4. Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries.
Matsumura M; Bhatt AS; Andress D; Clegg N; Takayama TK; Craik CS; Nelson PS
Prostate; 2005 Jan; 62(1):1-13. PubMed ID: 15389820
[TBL] [Abstract][Full Text] [Related]
5. Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR).
Beaufort N; Debela M; Creutzburg S; Kellermann J; Bode W; Schmitt M; Pidard D; Magdolen V
Biol Chem; 2006 Feb; 387(2):217-22. PubMed ID: 16497155
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen activates single-chain urokinase-type plasminogen activator.
Yoshida E; Ohmura S; Sugiki M; Maruyama M; Mihara H
Int J Cancer; 1995 Dec; 63(6):863-5. PubMed ID: 8847146
[TBL] [Abstract][Full Text] [Related]
7. Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing.
Denmeade SR; Lövgren J; Khan SR; Lilja H; Isaacs JT
Prostate; 2001 Jul; 48(2):122-6. PubMed ID: 11433422
[TBL] [Abstract][Full Text] [Related]
8. Urokinase-type plasminogen activator is a preferred substrate of the human epithelium serine protease tryptase epsilon/PRSS22.
Yasuda S; Morokawa N; Wong GW; Rossi A; Madhusudhan MS; Sali A; Askew YS; Adachi R; Silverman GA; Krilis SA; Stevens RL
Blood; 2005 May; 105(10):3893-901. PubMed ID: 15701722
[TBL] [Abstract][Full Text] [Related]
9. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells.
Veveris-Lowe TL; Lawrence MG; Collard RL; Bui L; Herington AC; Nicol DL; Clements JA
Endocr Relat Cancer; 2005 Sep; 12(3):631-43. PubMed ID: 16172196
[TBL] [Abstract][Full Text] [Related]
10. Crystal structures of human tissue kallikrein 4: activity modulation by a specific zinc binding site.
Debela M; Magdolen V; Grimminger V; Sommerhoff C; Messerschmidt A; Huber R; Friedrich R; Bode W; Goettig P
J Mol Biol; 2006 Oct; 362(5):1094-107. PubMed ID: 16950394
[TBL] [Abstract][Full Text] [Related]
11. Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1.
Mikolajczyk SD; Millar LS; Kumar A; Saedi MS
Int J Cancer; 1999 May; 81(3):438-42. PubMed ID: 10209959
[TBL] [Abstract][Full Text] [Related]
12. Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator.
Frenette G; Tremblay RR; Lazure C; Dube JY
Int J Cancer; 1997 May; 71(5):897-9. PubMed ID: 9180162
[TBL] [Abstract][Full Text] [Related]
13. Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry.
Obiezu CV; Soosaipillai A; Jung K; Stephan C; Scorilas A; Howarth DH; Diamandis EP
Clin Chem; 2002 Aug; 48(8):1232-40. PubMed ID: 12142379
[TBL] [Abstract][Full Text] [Related]
14. Expression and purification of recombinant active prostate-specific antigen from Escherichia coli.
Jeong S; Lee SW
J Microbiol Biotechnol; 2007 May; 17(5):840-6. PubMed ID: 18051307
[TBL] [Abstract][Full Text] [Related]
15. Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression.
Nelson PS; Gan L; Ferguson C; Moss P; Gelinas R; Hood L; Wang K
Proc Natl Acad Sci U S A; 1999 Mar; 96(6):3114-9. PubMed ID: 10077646
[TBL] [Abstract][Full Text] [Related]
16. A structural model for the prostate disease marker, human prostate-specific antigen.
Villoutreix BO; Getzoff ED; Griffin JH
Protein Sci; 1994 Nov; 3(11):2033-44. PubMed ID: 7535613
[TBL] [Abstract][Full Text] [Related]
17. Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I.
Robert M; Gibbs BF; Jacobson E; Gagnon C
Biochemistry; 1997 Apr; 36(13):3811-9. PubMed ID: 9092810
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice.
List K; Jensen ON; Bugge TH; Lund LR; Ploug M; Danø K; Behrendt N
Biochemistry; 2000 Jan; 39(3):508-15. PubMed ID: 10642175
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific kallikreins-2 and -4 enhance the proliferation of DU-145 prostate cancer cells through protease-activated receptors-1 and -2.
Mize GJ; Wang W; Takayama TK
Mol Cancer Res; 2008 Jun; 6(6):1043-51. PubMed ID: 18567807
[TBL] [Abstract][Full Text] [Related]
20. Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: nuclear, cytoplasmic and secreted forms.
Dong Y; Bui LT; Odorico DM; Tan OL; Myers SA; Samaratunga H; Gardiner RA; Clements JA
Endocr Relat Cancer; 2005 Dec; 12(4):875-89. PubMed ID: 16322328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
